Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Revenue of Eterna Therapeutics Inc. (ERNA)
Revenue in 2023 (TTM): $68 K
According to Eterna Therapeutics Inc.'s latest financial reports the company's current revenue (TTM) is $68 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Eterna Therapeutics Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $68 K | $-1,291,000 | $-19,551,000 | $-21,671,000 | $-21,668,000 |
| 2022 | $ | $-497,000 | $-32,032,000 | $-24,534,000 | $-24,579,000 |
| 2021 | $ | $-459,000 | $68.8 M | $-122,301,000 | $-122,306,000 |
| 2020 | $ | $-98,000 | $-7,150,000 | $-7,291,000 | $11.91 M |
| 2019 | $19.81 M | $11.96 M | $1.96 M | $-2,020,000 | $-2,047,000 |
| 2018 | $23.34 M | $14.95 M | $3.23 M | $-323,000 | $-259,000 |
| 2017 | $21.27 M | $14.19 M | $915 K | $-1,010,999 | $-1,077,000 |
| 2016 | $22.31 M | $14.18 M | $609 K | $-2,885,000 | $-2,923,000 |
| 2015 | $24.52 M | $11.46 M | $-3,496,000 | $-7,214,000 | $-7,226,000 |